{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "bb2efc9dcf7b1a65c9aea5574f7488c0",
    "title": "Jefferies",
    "source_uri": "2025-08-29/Return of the RaDaR Key Takes From NEOs Favorable Court Ruling Against NTRAReturn of the RaDaR Key Takes From NEOs Favor_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:44:39.345119",
      "extracted_at": "2025-10-27T00:44:39.345129"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 8,
        "successful_pages": 8,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 11,
          "reduction_ratio": 0.2858432880105266
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "18eecb84ea76b5b1",
      "text": "USA | Life Science Tools & Diagnostics",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "17eb9719e146efbb",
      "text": "Return of the RaDaR: **K** **e** **y** Takes From NEO'sFavorable Court RulingAgainst NTRA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "eae27c8d6e84d1ec",
      "text": "NEO shares are higher (&gt;20%) after a court ruling finding no patent infringement against NTRA, enabling the commercialization of RaDaR in MRD. Given RaDaR's previous CMS coverage, we see breast (&#36;3B+ TAM) as a logical starting point for NEO's new assay, with other indications (CRC, lung) to drive growth toward the LRP (DD+). On the cost side, NEO could see some alleviation on R&D (and need to pursue MRD M&A), while lower legal spend (&#36;14M/yr) should help FCF.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "334b1b9b7412ba36",
      "text": "**What happened.** NEO, whose original RaDaR MRD test was previously found to infringe on NTRA's Signatera patents, won a summary judgment that deemed all of NTRA's patent claims to be invalid as it relates to RaDaR ST (formerly known as RaDaR 1.1). This enables NEO to broadly commercialize its MRD assay, as RaDaR ST has already launched to biopharma customers, with NEO also submitting the test to CMS/MoIDX (within last few months) for clinical reimbursement coverage. Recall, expectations were previously set for an October ruling, and the uncertainty posed a major overhang on the stock (as evident by today's &gt;20% move higher on the news release). In light of the ruling, NTRA is evaluating its options, including an appeal and enforcement through other patents.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d3a48715e6494048",
      "text": "**Re-entering a massive MRD market.** As flagged in our deep dive, the MRD market presents a large &#36;20B+ TAM that remains underpenetrated (LSD%), despite recent market entries from several competitors, including EXAS, DGX, and LH, among other private companies. Based on the original RaDaR assay's commercial position, we view breast cancer as RaDaR 1.1's most significant near-term MRD opportunity, given the high U.S. incidence rate (ACS projects 317k female diagnoses in '25) and the fact that RaDaR was previously covered by Medicare for breast MRD. We see the scope for breast MRD to account for a &#36;3B+ TAM over time (~300k diagnoses * &#36;2k target ASP * 5 tests per patient - per year when combining cohorts), with market acceleration likely to exceed the current leading indication, CRC (as per our market model). The breast MRD market, plus additional opportunities for RaDaR ST in CRC, NSCLC, and head and neck MRD, could underpin NEO growth toward its LRP rate, which was previously +12-13% until mgmt. more recently reset the rate to +DD,with additional upside from pipeline tests (including MRD) and M&A.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e43927e9e22a1993",
      "text": "**Win helps margin levers,-FCF expansion, M&A optionality.** With NEO already having cleared CLIA validation in 1**12** (establishes clinical equivalency with v1.0) and submitted its MoIDx bridging study (for CMS reimbursement), RaDaR ST is operationally ready and poised for clinical launch (already launched to biopharma customers). While somewhat dependent on MoIDx decision (typically 120-180 days, so by year-end), the win today expedites the path to market, which NEO has been **he** **g**ing with its RaDaR 2.0 program (entirely new technology) that is still in early phases of development. Management has full intention of continuing to pursue v2.0, which should have **differ** **e** **r** ated sensitivity, but with ST/v1.1 now in play, NEO can manage spend accordingly, which **sh** **o** **r** **d** help path to LRP OPMX of +250bps/year. After all, R&D has ticked higher in 1H25 (+&#36;4m/40bps), with MRD commanding a \"significant\" portion. Most immediately, NEO should be able to cut back on its &gt;&#36;14M of annual IP litigation spend, which while already backed-out of adjusted P&L,will provide nice uplift to FCF, which has been negative for 19 of the last 22 quarters - as reminder,C DNA saw legal spend fall &gt;&#36;15M in '24 post NTRA lawsuit (resolved early that year).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b573eacc3d138377",
      "text": "Equity ResearchAugust 29,2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b854a35e6e2a649f",
      "text": "FLASH NOTERATINGBUYPRICE&#36;7.21*PRICE TARGET|% TO PT&#36;7.50|+4%52W HIGH-LOW&#36;19.12-&#36;4.72FLOAT (%)|ADV MM (USD)97.2%|19.05MARKET CAP&#36;922.5MTICKERNEO",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee61ff6b9b948d4a",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "365f513d0bc02b8a",
      "text": "**What happened.** NEO, whose original RaDaR MRD test was previously found to infringe on NTRA's Signatera patents, won a summary judgment that deemed all of NTRA's patent claims to be invalid as it relates to RaDaR ST (formerly known as RaDaR 1.1). This enables NEO to broadly commercialize its MRD assay, as RaDaR ST has already launched to biopharma customers, with NEO also submitting the test to CMS/MoIDX (within last few months) for clinical reimbursement coverage. Recall, expectations were previously set for an October ruling, and the uncertainty posed a major overhang on the stock (as evident by today's &gt;20% move higher on the news release). In light of the ruling, NTRA is evaluating its options, including an appeal and enforcement through other patents.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fc7126e71fccc47e",
      "text": "**Re-entering a massive MRD market.** As flagged in our deep dive, the MRD market presents a large &#36;20B+ TAM that remains underpenetrated (LSD%), despite recent market entries from several competitors, including EXAS, DGX, and LH, among other private companies. Based on the original RaDaR assay's commercial position, we view breast cancer as RaDaR 1.1's most significant near-term MRD opportunity, given the high U.S. incidence rate (ACS projects 317k female diagnoses in '25) and the fact that RaDaR was previously covered by Medicare for breast MRD. We see the scope for breast MRD to account for a &#36;3B+ TAM over time (~300k diagnoses * &#36;2k target ASP * 5 tests per patient - per year when combining cohorts), with market acceleration likely to exceed the current leading indication, CRC (as per our market model). The breast MRD market, plus additional opportunities for RaDaR ST in CRC, NSCLC, and head and neck MRD, could underpin NEO growth toward its LRP rate, which was previously +12-13% until mgmt. more recently reset the rate to +DD,with additional upside from pipeline tests (including MRD) and M&A.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d2e3753b209c2291",
      "text": "**Win helps margin levers,-FCF expansion, M&A optionality.** With NEO already having cleared CLIA validation in 1**12** (establishes clinical equivalency with v1.0) and submitted its MoIDx bridging study (for CMS reimbursement), RaDaR ST is operationally ready and poised for clinical launch (already launched to biopharma customers). While somewhat dependent on MoIDx decision (typically 120-180 days, so by year-end), the win today expedites the path to market, which NEO has been **he** **g**ing with its RaDaR 2.0 program (entirely new technology) that is still in early phases of development. Management has full intention of continuing to pursue v2.0, which should have **differ** **e** **r** ated sensitivity, but with ST/v1.1 now in play, NEO can manage spend accordingly, which **sh** **o** **r** **d** help path to LRP OPMX of +250bps/year. After all, R&D has ticked higher in 1H25 (+&#36;4m/40bps), with MRD commanding a \"significant\" portion. Most immediately, NEO should be able to cut back on its &gt;&#36;14M of annual IP litigation spend, which while already backed-out of adjusted P&L,will provide nice uplift to FCF, which has been negative for 19 of the last 22 quarters - as reminder,C DNA saw legal spend fall &gt;&#36;15M in '24 post NTRA lawsuit (resolved early that year).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "eae5f91cb4b586bb",
      "text": "NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. The Company leverages its expertise in clinical cancer testing, molecular and NGS testing with the goal of improving patient care and saving lives.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0fd603eecd40c577",
      "text": "DCF- derived PT of \\(\\) 7.50\\(is 1.5x'26E sales. Risks: 1) NTRA litigation; 2) competitive pressure in NGS; 3) dilutive M&A",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5f99fe9775862bc5",
      "text": "Our \\(\\) 80\\(PT is supported by our DCF and implies\\) \\sim 5x\\(our'25E revs / 25x our'25E EBITDA. Risks include pipeline execution (development and commercialization milestones), commercial execution (key source of future operating leverage), ability to sustain positive FCF, and liquid biopsy competition.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "74c60fa07689b35a",
      "text": "Our \\(\\) 300\\(PT is based on a\\) \\sim 12x\\(EBITDA multiple and our DCF estimates. Risks: Inflated labor costs contribute to continued margin compression, more lab volume shifts to competitors than expected; market share gains from independent & regional labs are less than expected",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b154f95ce980423e",
      "text": "Our \\(\\) 200\\(PT is supported by our DCF and implies\\) \\sim 11x'26E EV/revs. Risks: unsuccessful IP litigation, strict LDT regulation, unfavorable reimbursement rates and/or policies, disruption in sole- source supplier (Illumina).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d403c00e8f539d83",
      "text": "Our \\(\\) 200\\(PT is based on\\) \\sim 12x'26E EBITDA and our DCF estimates. Risks: Market share gains from independent & regional labs are less than expected; pricing pressure.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "707a4e3c56bca4e1",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cbbb029011356b05",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4961106c5ffae8dc",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e792b91bb7e03ed8",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1ec3a722daeac8d1",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2a239f8b4858a797",
      "text": "Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "158f9588276156ce",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "586a4105c00baf76",
      "text": "- Exact Sciences Corporation (EXAS: \\(46.95, \\text{BUY})\\) - Labcorp Holdings (LH: \\$275.29, \\text{BUY}) - Natera Inc (NTRA: \\$167.88, \\text{BUY}) - NeoGenomics, Inc. (NEO: \\$7.21, \\text{BUY}) - Quest Diagnostics Incorporated (DGX: \\$179.20, \\text{BUY})",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "86f2b2d993e95895",
      "text": "Rating and Price Target History for: NeoGenomics, Inc. (NEO) as of 08-28-2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3f066be398992247",
      "text": "Rating and Price Target History for: Quest Diagnostics Incorporated (DGX) as of 08-28-2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8b7dac90dac793f4",
      "text": "Rating and Price Target History for: Exact Sciences Corporation (EXAS) as of 08-28-2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8c76eb4b14e9f15e",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4e8059dbe57f45d8",
      "text": "I: Initiating Coverage",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b3aedf9444f93577",
      "text": "Distribution of Ratings",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f57eccec322728b8",
      "text": "Distribution of RatingsIB Serv./Past12 Mos.JIL Mkt Serv./Past12 Mos.CountPercentCountPercentCountPercentBUY211160.63%37017.53%1185.59%HOLD121334.84%1058.66%221.81%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b3ce58344976d619",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "90edd3add09751c6",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8e84e209e6726dd2",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "883303f344384416",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "90218a75f45f92de",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4062a2ffa453ffad",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "4f39357d9811544a",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "849657c01147d42c",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f21450c28b308c37",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5b937986669e3b89",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "602904a44357019b",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "81a8df2024c48fc0",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1adbead7418a2d32",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9b8512756ed14216",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "67a16e67775bdb08",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "58f37497184b7d1f",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0af41a2a27e92d26",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ab8309ce43ab18d8",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 7,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "81fac3e5d419587d",
      "name": "Corporation\n\nOur",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1ab895eb8e382eb8",
      "name": "Court RulingAgainst",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "40a941c3adbea944",
      "name": "Diagnostics\n\nNeoGenomics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3a9f1e728b314846",
      "name": "Disclosures\n\nJefferies",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a87247c304f6889b",
      "name": "Dropped Coverage",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8ed3fafbb18d7293",
      "name": "Dubai Financial",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4cf520d9cd23c4b2",
      "name": "Equity ResearchAugust",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "21bc9aa97d2d9364",
      "name": "European Economic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1be28e588f1353cd",
      "name": "Exact Sciences",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "99f9c4a8601964a4",
      "name": "Exact Sciences Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "88ae349d7f27936d",
      "name": "Exchange Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c30d804de2e4ac53",
      "name": "Financial Conduct",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f279b250fb9ccc9a",
      "name": "Financial Services",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9acf1646d3aff849",
      "name": "For Canadian",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": "Investment Recommendation Record",
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "10f9ca31e5c06108",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Labcorp Holdings (LH) as of 08-28-2025",
        "page": 5,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 160,
              "max": 300
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "$",
            "values": [
              {
                "date": "10/05/2022",
                "value": 260.0
              },
              {
                "date": "02/14/2023",
                "value": 285.0
              },
              {
                "date": "10/13/2023",
                "value": 235.0
              },
              {
                "date": "11/20/2023",
                "value": 245.0
              },
              {
                "date": "09/23/2024",
                "value": 265.0
              },
              {
                "date": "12/09/2024",
                "value": 275.0
              },
              {
                "date": "02/06/2025",
                "value": 290.0
              },
              {
                "date": "07/24/2025",
                "value": 300.0
              }
            ]
          }
        ],
        "figure_id": "881c4f12a298a4d2",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Natera Inc (NTRA) as of 08-28-2025",
        "page": 5,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 20,
              "max": 180
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "$",
            "values": [
              {
                "date": "2022-10",
                "value": 40
              },
              {
                "date": "2023-01",
                "value": 50
              },
              {
                "date": "2023-04",
                "value": 60
              },
              {
                "date": "2023-07",
                "value": 50
              },
              {
                "date": "2023-10",
                "value": 70
              },
              {
                "date": "2024-01",
                "value": 90
              },
              {
                "date": "2024-04",
                "value": 110
              },
              {
                "date": "2024-07",
                "value": 140
              },
              {
                "date": "2024-10",
                "value": 170
              },
              {
                "date": "2025-01",
                "value": 160
              },
              {
                "date": "2025-04",
                "value": 140
              },
              {
                "date": "2025-07",
                "value": 160
              }
            ]
          },
          {
            "name": "BUY Target",
            "unit": "$",
            "values": [
              {
                "date": "2024-06-03",
                "value": 142.0
              },
              {
                "date": "2024-11-13",
                "value": 182.0
              },
              {
                "date": "2025-02-27",
                "value": 195.0
              },
              {
                "date": "2025-05-08",
                "value": 200.0
              }
            ]
          }
        ],
        "figure_id": "c535973c8749390e",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "a59d1b85a12b0818",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 110,
              "max": 190
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "$",
            "values": [
              {
                "date": "2022-10-01",
                "value": 115
              },
              {
                "date": "2022-11-07",
                "value": 140
              },
              {
                "date": "2022-12-01",
                "value": 150
              },
              {
                "date": "2023-01-01",
                "value": 155
              },
              {
                "date": "2023-02-01",
                "value": 150
              },
              {
                "date": "2023-03-01",
                "value": 145
              },
              {
                "date": "2023-04-01",
                "value": 140
              },
              {
                "date": "2023-05-01",
                "value": 135
              },
              {
                "date": "2023-06-01",
                "value": 130
              },
              {
                "date": "2023-07-01",
                "value": 125
              },
              {
                "date": "2023-08-01",
                "value": 120
              },
              {
                "date": "2023-09-01",
                "value": 125
              },
              {
                "date": "2023-10-13",
                "value": 136
              },
              {
                "date": "2023-11-01",
                "value": 135
              },
              {
                "date": "2023-11-20",
                "value": 140
              },
              {
                "date": "2023-12-01",
                "value": 145
              },
              {
                "date": "2024-01-01",
                "value": 150
              },
              {
                "date": "2024-02-01",
                "value": 155
              },
              {
                "date": "2024-02-07",
                "value": 155
              },
              {
                "date": "2024-03-01",
                "value": 160
              },
              {
                "date": "2024-04-01",
                "value": 165
              },
              {
                "date": "2024-04-24",
                "value": 160
              },
              {
                "date": "2024-05-01",
                "value": 165
              },
              {
                "date": "2024-06-01",
                "value": 170
              },
              {
                "date": "2024-07-01",
                "value": 175
              },
              {
                "date": "2024-08-01",
                "value": 170
              },
              {
                "date": "2024-09-01",
                "value": 175
              },
              {
                "date": "2024-09-23",
                "value": 175
              },
              {
                "date": "2024-10-01",
                "value": 170
              },
              {
                "date": "2024-11-01",
                "value": 165
              },
              {
                "date": "2024-12-01",
                "value": 170
              },
              {
                "date": "2024-12-09",
                "value": 185
              },
              {
                "date": "2025-01-01",
                "value": 175
              },
              {
                "date": "2025-01-30",
                "value": 190
              },
              {
                "date": "2025-02-01",
                "value": 180
              },
              {
                "date": "2025-03-01",
                "value": 175
              },
              {
                "date": "2025-04-01",
                "value": 170
              },
              {
                "date": "2025-04-22",
                "value": 195
              },
              {
                "date": "2025-05-01",
                "value": 175
              },
              {
                "date": "2025-06-01",
                "value": 180
              },
              {
                "date": "2025-07-01",
                "value": 185
              },
              {
                "date": "2025-07-22",
                "value": 200
              }
            ]
          }
        ],
        "figure_id": "a80fd70be9214e46",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 25
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": null,
            "values": [
              7.5,
              12.5,
              19.5,
              15.0,
              12.0,
              19.0,
              15.0,
              16.0,
              18.5,
              10.0,
              7.0,
              8.0
            ]
          }
        ],
        "figure_id": "31ae75c0e166d0bc",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 30,
              "max": 110
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "$",
            "values": [
              {
                "date": "2022-10-01",
                "value": 35
              },
              {
                "date": "2022-12-02",
                "value": 70
              },
              {
                "date": "2023-02-22",
                "value": 72
              },
              {
                "date": "2023-05-10",
                "value": 82
              },
              {
                "date": "2023-06-07",
                "value": 100
              },
              {
                "date": "2023-08-02",
                "value": 110
              },
              {
                "date": "2023-11-02",
                "value": 95
              },
              {
                "date": "2024-02-22",
                "value": 85
              },
              {
                "date": "2024-06-03",
                "value": 75
              },
              {
                "date": "2024-07-31",
                "value": 84
              },
              {
                "date": "2024-11-05",
                "value": 85
              },
              {
                "date": "2025-02-19",
                "value": 80
              }
            ]
          }
        ],
        "figure_id": "fed45af532d8c967",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "ac3a5fec2dbb44b4",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "R: **K** **e** **y** Takes From NEO'sFavorable Court RulingAgainst NTRA NEO shares are higher (&gt;20%) after a court ruling finding no patent infringement against NTRA, enabling the commercialization",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b9ded49175e19cd8",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "October ruling, and the uncertainty posed a major overhang on the stock (as evident by today's &gt;20% move higher on the news release). In light of the ruling, NTRA is evaluating its options, includi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "50850a2634ade886",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SCLC, and head and neck MRD, could underpin NEO growth toward its LRP rate, which was previously +12-13% until mgmt. more recently reset the rate to +DD,with additional upside from pipeline tests (inc",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f9af8bbb2955b4c0",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Y</td></tr><tr><td>PRICE</td><td>&#36;7.21*</td></tr><tr><td>PRICE TARGET|% TO PT</td><td>&#36;7.50|+4%</td></tr><tr><td>52W HIGH-LOW</td><td>&#36;19.12-&#36;4.72</td></tr><tr><td>FLOAT (%)|ADV MM (US",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1ff839009847cceb",
        "value": 0.972,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>52W HIGH-LOW</td><td>&#36;19.12-&#36;4.72</td></tr><tr><td>FLOAT (%)|ADV MM (USD)</td><td>97.2%|19.05</td></tr><tr><td>MARKET CAP</td><td>&#36;922.5M</td></tr><tr><td>TICKER</td><td>NEO</td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b9ded49175e19cd8",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "October ruling, and the uncertainty posed a major overhang on the stock (as evident by today's &gt;20% move higher on the news release). In light of the ruling, NTRA is evaluating its options, includi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "50850a2634ade886",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SCLC, and head and neck MRD, could underpin NEO growth toward its LRP rate, which was previously +12-13% until mgmt. more recently reset the rate to +DD,with additional upside from pipeline tests (inc",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d9e7bc731142b00b",
        "value": 275.29,
        "unit": "$",
        "metric_type": "currency",
        "context": "in This Report - Exact Sciences Corporation (EXAS: \\(46.95, \\text{BUY})\\) - Labcorp Holdings (LH: \\$275.29, \\text{BUY}) - Natera Inc (NTRA: \\$167.88, \\text{BUY}) - NeoGenomics, Inc. (NEO: \\$7.21, \\tex",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "51614d8b5d9890b3",
        "value": 167.88,
        "unit": "$",
        "metric_type": "currency",
        "context": "on (EXAS: \\(46.95, \\text{BUY})\\) - Labcorp Holdings (LH: \\$275.29, \\text{BUY}) - Natera Inc (NTRA: \\$167.88, \\text{BUY}) - NeoGenomics, Inc. (NEO: \\$7.21, \\text{BUY}) - Quest Diagnostics Incorporated ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "01c0c7bbdff853b6",
        "value": 7.21,
        "unit": "$",
        "metric_type": "currency",
        "context": "ngs (LH: \\$275.29, \\text{BUY}) - Natera Inc (NTRA: \\$167.88, \\text{BUY}) - NeoGenomics, Inc. (NEO: \\$7.21, \\text{BUY}) - Quest Diagnostics Incorporated (DGX: \\$179.20, \\text{BUY})<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "13c4e0711f76899d",
        "value": 179.2,
        "unit": "$",
        "metric_type": "currency",
        "context": ", \\text{BUY}) - NeoGenomics, Inc. (NEO: \\$7.21, \\text{BUY}) - Quest Diagnostics Incorporated (DGX: \\$179.20, \\text{BUY})<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a861e6aaff89b474",
        "value": 0.6063000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "92563a1ce962bf67",
        "value": 0.1753,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b70a448bbad1c50d",
        "value": 0.0559,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1876a4de4e5d4526",
        "value": 0.34840000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4984764782ea08c0",
        "value": 0.0866,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "631f350f465d5caf",
        "value": 0.0181,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f40406ff71f32863",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6b97f31d5b869062",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "408d15809a0b4cbc",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 7,
      "tables_count": 0,
      "numerical_data_count": 20,
      "passages_count": 51,
      "entities_count": 20
    }
  }
}